vs

Side-by-side financial comparison of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) and SolarMax Technology, Inc. (SMXT). Click either name above to swap in a different company.

MARAVAI LIFESCIENCES HOLDINGS, INC. is the larger business by last-quarter revenue ($49.9M vs $46.6M, roughly 1.1× SolarMax Technology, Inc.). SolarMax Technology, Inc. runs the higher net margin — -1.9% vs -71.6%, a 69.7% gap on every dollar of revenue. On growth, SolarMax Technology, Inc. posted the faster year-over-year revenue change (623.5% vs -11.8%).

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

SolarMax Technology, Inc. develops, manufactures and sells high-efficiency solar PV modules and clean energy systems. It serves residential, commercial and industrial clients in North America and key Asia-Pacific markets, offering installation and after-sales support to boost low-carbon energy use.

MRVI vs SMXT — Head-to-Head

Bigger by revenue
MRVI
MRVI
1.1× larger
MRVI
$49.9M
$46.6M
SMXT
Growing faster (revenue YoY)
SMXT
SMXT
+635.3% gap
SMXT
623.5%
-11.8%
MRVI
Higher net margin
SMXT
SMXT
69.7% more per $
SMXT
-1.9%
-71.6%
MRVI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MRVI
MRVI
SMXT
SMXT
Revenue
$49.9M
$46.6M
Net Profit
$-35.7M
$-872.2K
Gross Margin
25.8%
2.7%
Operating Margin
-117.9%
-2.7%
Net Margin
-71.6%
-1.9%
Revenue YoY
-11.8%
623.5%
Net Profit YoY
-37.7%
77.7%
EPS (diluted)
$-0.24
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRVI
MRVI
SMXT
SMXT
Q4 25
$49.9M
$46.6M
Q3 25
$41.6M
$30.6M
Q2 25
$47.4M
$6.9M
Q1 25
$46.9M
$6.9M
Q4 24
$56.6M
$6.4M
Q3 24
$69.0M
$6.3M
Q2 24
$69.4M
Q1 24
$64.2M
Net Profit
MRVI
MRVI
SMXT
SMXT
Q4 25
$-35.7M
$-872.2K
Q3 25
$-25.6M
$-2.3M
Q2 25
$-39.6M
$-1.9M
Q1 25
$-29.9M
$-1.3M
Q4 24
$-25.9M
$-3.9M
Q3 24
$-97.1M
$-9.6M
Q2 24
$-9.8M
Q1 24
$-12.1M
Gross Margin
MRVI
MRVI
SMXT
SMXT
Q4 25
25.8%
2.7%
Q3 25
13.6%
3.1%
Q2 25
16.4%
8.8%
Q1 25
16.5%
20.5%
Q4 24
34.3%
14.5%
Q3 24
46.7%
19.9%
Q2 24
44.4%
Q1 24
40.3%
Operating Margin
MRVI
MRVI
SMXT
SMXT
Q4 25
-117.9%
-2.7%
Q3 25
-98.6%
-6.9%
Q2 25
-139.8%
-25.7%
Q1 25
-104.9%
-16.7%
Q4 24
-66.7%
-27.9%
Q3 24
-239.9%
-158.4%
Q2 24
-19.4%
Q1 24
-29.4%
Net Margin
MRVI
MRVI
SMXT
SMXT
Q4 25
-71.6%
-1.9%
Q3 25
-61.4%
-7.4%
Q2 25
-83.5%
-27.6%
Q1 25
-63.9%
-18.7%
Q4 24
-45.8%
-60.6%
Q3 24
-140.6%
-152.0%
Q2 24
-14.1%
Q1 24
-18.8%
EPS (diluted)
MRVI
MRVI
SMXT
SMXT
Q4 25
$-0.24
$-0.02
Q3 25
$-0.18
$-0.04
Q2 25
$-0.27
$-0.04
Q1 25
$-0.21
$-0.03
Q4 24
$-0.21
$-0.07
Q3 24
$-0.68
$-0.21
Q2 24
$-0.07
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRVI
MRVI
SMXT
SMXT
Cash + ST InvestmentsLiquidity on hand
$216.9M
$8.0M
Total DebtLower is stronger
$291.8M
Stockholders' EquityBook value
$212.4M
$-12.2M
Total Assets
$770.6M
$91.3M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRVI
MRVI
SMXT
SMXT
Q4 25
$216.9M
$8.0M
Q3 25
$243.6M
$5.7M
Q2 25
$269.9M
$1.9M
Q1 25
$285.1M
$6.8M
Q4 24
$322.4M
$7.1M
Q3 24
$578.2M
$8.6M
Q2 24
$573.2M
Q1 24
$561.7M
Total Debt
MRVI
MRVI
SMXT
SMXT
Q4 25
$291.8M
Q3 25
$292.8M
Q2 25
$293.9M
Q1 25
$294.9M
Q4 24
$295.9M
Q3 24
$521.7M
Q2 24
$522.5M
Q1 24
$523.3M
Stockholders' Equity
MRVI
MRVI
SMXT
SMXT
Q4 25
$212.4M
$-12.2M
Q3 25
$245.4M
$-11.8M
Q2 25
$265.9M
$-15.1M
Q1 25
$300.6M
$-15.9M
Q4 24
$325.3M
$-15.1M
Q3 24
$344.9M
$-10.9M
Q2 24
$434.7M
Q1 24
$410.7M
Total Assets
MRVI
MRVI
SMXT
SMXT
Q4 25
$770.6M
$91.3M
Q3 25
$849.2M
$58.7M
Q2 25
$897.0M
$38.2M
Q1 25
$959.8M
$38.6M
Q4 24
$1.0B
$38.6M
Q3 24
$1.3B
$43.0M
Q2 24
$1.4B
Q1 24
$1.4B
Debt / Equity
MRVI
MRVI
SMXT
SMXT
Q4 25
1.37×
Q3 25
1.19×
Q2 25
1.11×
Q1 25
0.98×
Q4 24
0.91×
Q3 24
1.51×
Q2 24
1.20×
Q1 24
1.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRVI
MRVI
SMXT
SMXT
Operating Cash FlowLast quarter
$-22.8M
$-2.5M
Free Cash FlowOCF − Capex
$-24.9M
FCF MarginFCF / Revenue
-49.9%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-70.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRVI
MRVI
SMXT
SMXT
Q4 25
$-22.8M
$-2.5M
Q3 25
$-15.2M
$3.4M
Q2 25
$-10.3M
$220.7K
Q1 25
$-9.4M
$-601.1K
Q4 24
$-14.6M
$-1.3M
Q3 24
$13.1M
$203.6K
Q2 24
$17.4M
Q1 24
$-8.5M
Free Cash Flow
MRVI
MRVI
SMXT
SMXT
Q4 25
$-24.9M
Q3 25
$-18.1M
Q2 25
$-13.1M
Q1 25
$-14.6M
Q4 24
$-20.5M
Q3 24
$4.5M
Q2 24
$7.9M
Q1 24
$-14.1M
FCF Margin
MRVI
MRVI
SMXT
SMXT
Q4 25
-49.9%
Q3 25
-43.4%
Q2 25
-27.7%
Q1 25
-31.2%
Q4 24
-36.2%
Q3 24
6.6%
Q2 24
11.4%
Q1 24
-22.0%
Capex Intensity
MRVI
MRVI
SMXT
SMXT
Q4 25
4.2%
Q3 25
7.0%
Q2 25
6.1%
Q1 25
11.2%
Q4 24
10.3%
Q3 24
12.4%
0.0%
Q2 24
13.8%
Q1 24
8.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

SMXT
SMXT

Yabucoa$35.9M77%
Other$10.7M23%

Related Comparisons